REGENERELLE (TM)
Mesenchymal Stromal Cell Manufacturer
THE GOLD STANDARD
MSC from Wharton's Jelly
Mesenchymal Stroma Cells derived from Wharton's jelly in human umbilical cords exhibit superior proliferation and differentiation potential and are an emerging therapy option and agent in regenerative medicine.
Regenerelle stem cells are the gold standard of MSCs. Highest potency and purity, with stringent CLIA Lab quality testing at every step of the process from isolation, expansion and cryostorage.
OUR TECHNOLOGY
Smart solutions are at the core of all that we do at Regenerelle. Our main goal is finding smart ways of using technology that will help build a better tomorrow for everyone, everywhere. Click below to learn more about the technology behind our Biotechnology Regenerative Manufacturing company, or get in touch to set up a meeting with one of our representatives.
OUR STORY
How We Got Here
TEAM
We’re an experienced and talented group of entrepreneurs, engineers and doctors with a groundbreaking "Fight the Virus" idea that we hope will contribute towards a better tomorrow. We provide smart solutions for doctors and researchers who are dedicated to delivering a potential long lasting cure to those patients suffering with COVID and COVID long-haulers symptoms. Our goal is to get Doctors the regenerative tools they need to get patients suffering from long-haulers symptoms back on their feet enjoying an active life again!
MISSION
At Regenerelle, we believe that the right understanding of stem cells and technological edge can lead doctors towards providing patients with a healthy and successful future. Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) from Wharton's jelly are a promising therapeutic option for patients suffering from COVID long-haulers. Puren Hospital affiliated to Wuhan University of Science and Technology conducted the first successful small clinical trial using MSCs for severe COVID-19 patients with acute respiratory distress syndrome (ARDS). The clinical results published were tremendously successful. Doctors and researchers from around the world have responded to this study in a big way and have submitted fast track requests to the FDA to approve MSCs as a therapeutic treatment for patients suffering with ARDS from Covid-19. Our team at Regenerelle is uniquely positioned with 6,000 Sq Ft. of available ISO 7 compliant clean labs to join the war efforts and start incubating, expanding and processing MSCs to meet the need of patients in the US and around the world suffering from both COVID-19 ARDS and COVID- long-haulers
OUR LABS
Our 6,400 Sq. Ft ISO 7 compliant clean labs are producing a massive supply of MSCs, the likely key to help patients with severe ARDS and COVID long-haulers. In June 2021 Regenerelle received a $200,000 Federal Grant to support businesses fighting against COVID. This equipment grant will allow our production to scale up.
Its time to ramp up manufacturing now!
"The secret of getting ahead is getting started"